Next Article in Journal
Animal Models for Henipavirus Research
Previous Article in Journal
Retention in Care and Virological Failure among Adult HIV-Positive Patients on First-Line Antiretroviral Treatment in Maputo, Mozambique
Previous Article in Special Issue
Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Viruses
Volume 15
Issue 10
10.3390/v15101979
viruses-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Correction to Viruses 2023, 15(6), 1252.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Kaewchim et al. Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies. Viruses 2023, 15, 1252

by
Kanasap Kaewchim
1,2,
Kittirat Glab-ampai
2,
Kodchakorn Mahasongkram
2,
Thanatsaran Saenlom
2,
Watayagorn Thepsawat
2,
Monrat Chulanetra
2,
Kiattawee Choowongkomon
3,
Nitat Sookrung
2,4 and
Wanpen Chaicumpa
2,*
1
Graduate Program in Immunology, Department of Immunology, Faculty of Medicine Siriraj Hospital, Bangkok 10700, Thailand
2
Center of Research Excellence in Therapeutic Proteins and Antibody Engineering, Department of Parasitology, Faculty of Medicine Siriraj Hospital, Bangkok 10700, Thailand
3
Department of Biochemistry, Faculty of Sciences, Kasetsart University, Bangkok 10900, Thailand
4
Biomedical Research Incubator Unit, Department of Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
*
Author to whom correspondence should be addressed.
Viruses 2023, 15(10), 1979; https://doi.org/10.3390/v15101979
Submission received: 7 September 2023 / Accepted: 14 September 2023 / Published: 22 September 2023
(This article belongs to the Special Issue Nanomedicine Applied in the Control and Diagnosis of Viral Infections)
Browse Figure
Versions Notes

Error in Figure

In the original publication [1], there was a mistake in Figure 6. The published Figure 6 is a duplicate of Figure 2B. The correct Figure 6 appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated. The images were correct in the proofreading version, but the images might have been mixed up when we checked the proof. We apologize for the error.

Reference

  1. Kaewchim, K.; Glab-ampai, K.; Mahasongkram, K.; Saenlom, T.; Thepsawat, W.; Chulanetra, M.; Choowongkomon, K.; Sookrung, N.; Chaicumpa, W. Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies. Viruses 2023, 15, 1252. [Google Scholar] [CrossRef] [PubMed]
Viruses 15 01979 g006
Figure 6. Peptide-binding ELISA to demonstrate binding of the nanobodies to the RBD peptides. The nanobodies VH103 bound to VH103-P1 (P1), VH103-P2 (P2), and VH103-P3 (P3); VH105 bound to VH105-P4 (P4), VH105-P5 (P5), and VH105-P6 (P6); VH114 bound to VH114-P7 (P7); and VH278 bound to VH278-P8 (P8), which verified that the consensus peptides contained epitopes of the respective nanobodies. Control (irrelevant) peptide was included in the assay as negative control.
Figure 6. Peptide-binding ELISA to demonstrate binding of the nanobodies to the RBD peptides. The nanobodies VH103 bound to VH103-P1 (P1), VH103-P2 (P2), and VH103-P3 (P3); VH105 bound to VH105-P4 (P4), VH105-P5 (P5), and VH105-P6 (P6); VH114 bound to VH114-P7 (P7); and VH278 bound to VH278-P8 (P8), which verified that the consensus peptides contained epitopes of the respective nanobodies. Control (irrelevant) peptide was included in the assay as negative control.
Viruses 15 01979 g006
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Kaewchim, K.; Glab-ampai, K.; Mahasongkram, K.; Saenlom, T.; Thepsawat, W.; Chulanetra, M.; Choowongkomon, K.; Sookrung, N.; Chaicumpa, W. Correction: Kaewchim et al. Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies. Viruses 2023, 15, 1252. Viruses 2023, 15, 1979. https://doi.org/10.3390/v15101979

AMA Style

Kaewchim K, Glab-ampai K, Mahasongkram K, Saenlom T, Thepsawat W, Chulanetra M, Choowongkomon K, Sookrung N, Chaicumpa W. Correction: Kaewchim et al. Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies. Viruses 2023, 15, 1252. Viruses. 2023; 15(10):1979. https://doi.org/10.3390/v15101979

Chicago/Turabian Style

Kaewchim, Kanasap, Kittirat Glab-ampai, Kodchakorn Mahasongkram, Thanatsaran Saenlom, Watayagorn Thepsawat, Monrat Chulanetra, Kiattawee Choowongkomon, Nitat Sookrung, and Wanpen Chaicumpa. 2023. "Correction: Kaewchim et al. Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies. Viruses 2023, 15, 1252" Viruses 15, no. 10: 1979. https://doi.org/10.3390/v15101979

APA Style

Kaewchim, K., Glab-ampai, K., Mahasongkram, K., Saenlom, T., Thepsawat, W., Chulanetra, M., Choowongkomon, K., Sookrung, N., & Chaicumpa, W. (2023). Correction: Kaewchim et al. Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies. Viruses 2023, 15, 1252. Viruses, 15(10), 1979. https://doi.org/10.3390/v15101979

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop